OverviewChartNewsTraderScreen

BAVARIAN NORDIC A/S/  DK0015998017  /

Turquoise
5/30/2024  4:54:00 PM Chg. +1.90 Volume Bid- Ask- High Low
177.45DKK +1.08% 4,922
Turnover: 871,367.03		 -Bid Size: - -Ask Size: - 178.40 175.15
GlobeNewswire 5/7 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 4/29 Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire 4/2 Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 2/23 Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire 2/15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 11/9/2023 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 11/8/2023 Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GlobeNewswire 9/21/2023 Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
TeleTrader 8/19/2022 EU makes monkeypox vaccine more available
TeleTrader 8/18/2022 WH announces new strategies against monkeypox
TeleTrader 7/30/2022 Spain confirms second monkeypox death
TeleTrader 7/29/2022 Spain confirms Europe's first monkeypox death
TeleTrader 7/25/2022 Monkeypox vaccine approved by EU
TeleTrader 7/22/2022 EMA gives preliminary approval to monkeypox jab
TeleTrader 6/14/2022 EU buys 110,000 monkeypox vaccines
TeleTrader 5/27/2022 EU to jointly buy antivirals, vaccines against monkeypox
GlobeNewswire 3/24/2022 Valneva Reports Full Year 2021 Results and Provides Corporate Updates
GlobeNewswire 3/21/2022 Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire 2/28/2022 Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire 2/14/2022 Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire 2/3/2022 Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
GlobeNewswire 12/6/2021 Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...
GlobeNewswire 12/5/2021 Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
GlobeNewswire 11/18/2021 Valneva Reports Nine-Month 2021 Revenue and Cash